Severe	severe	O	O	O	O
citrate	citrate	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
complicating	complicating	O	O	O	O
volunteer	volunteer	O	O	O	O
apheresis	apheresis	O	O	O	O
platelet	platelet	O	O	O	O
donation	donation	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
citrate	citrate	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
during	during	O	O	O	O
volunteer	volunteer	O	O	O	O
donor	donor	O	O	O	O
apheresis	apheresis	O	O	O	O
platelet	platelet	O	O	O	O
collection	collection	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
donor	donor	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
40-year-old	40-year-old	O	O	O	O
female	female	O	O	O	O
,	,	O	O	O	O
first-time	first-time	O	O	O	O
apheresis	apheresis	O	O	O	O
platelet	platelet	O	O	O	O
donor	donor	O	O	O	O
.	.	O	O	O	O

Past	past	O	O	O	O
medical	medical	O	O	O	O
history	history	O	O	O	O
was	was	O	O	O	O
remarkable	remarkable	O	O	O	O
for	for	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
hyperlipidemia	hyperlipidemia	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
depression	depression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Reported	reported	O	O	O	O
medications	medications	O	O	O	O
included	included	O	O	O	O
bumetanide	bumetanide	O	O	OTHERS	I
,	,	O	O	O	O
pravastatin	pravastatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Thirty	thirty	O	O	O	O
minutes	minutes	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
start	start	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
procedure	procedure	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
donor	donor	O	O	O	O
noted	noted	O	O	O	O
tingling	tingling	O	O	O	O
around	around	O	O	O	O
the	the	O	O	O	O
mouth	mouth	O	O	O	O
,	,	O	O	O	O
hands	hands	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
feet	feet	O	O	O	O
.	.	O	O	O	O

She	she	O	O	O	O
then	then	O	O	O	O
very	very	O	O	O	O
rapidly	rapidly	O	O	O	O
developed	developed	O	O	O	O
acute	acute	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
facial	facial	O	O	O	O
and	and	O	O	O	O
extremity	extremity	O	O	O	O
tetany	tetany	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Empirical	empirical	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
intravenous	intravenous	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
gluconate	gluconate	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
initiated	initiated	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
muscle	muscle	O	O	OTHERS	I
contractions	contractions	O	O	OTHERS	I
slowly	slowly	O	O	O	O
subsided	subsided	O	O	O	O
over	over	O	O	O	O
approximately	approximately	O	O	O	O
10	10	O	O	O	O
to	to	O	O	O	O
15	15	O	O	O	O
minutes	minutes	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
events	events	O	O	O	O
are	are	O	O	O	O
consistent	consistent	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
severe	severe	O	O	O	O
reaction	reaction	O	O	O	O
to	to	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
chelation	chelation	O	O	O	O
by	by	O	O	O	O
sodium	sodium	CHEMICALS	O	OTHERS	I
citrate	citrate	CHEMICALS	O	OTHERS	I
anticoagulant	anticoagulant	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
symptomatic	symptomatic	O	O	O	O
systemic	systemic	O	O	O	O
hypocalcemia	hypocalcemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Upon	upon	O	O	O	O
additional	additional	O	O	O	O
retrospective	retrospective	O	O	O	O
analysis	analysis	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
was	was	O	O	O	O
noted	noted	O	O	O	O
that	that	O	O	O	O
bumetanide	bumetanide	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
loop	loop	O	O	OTHERS	I
diuretic	diuretic	O	O	OTHERS	I
that	that	O	O	O	O
may	may	O	O	O	O
cause	cause	O	O	O	O
significant	significant	O	O	O	O
hypocalcemia	hypocalcemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
conclude	conclude	O	O	O	O
that	that	O	O	O	O
careful	careful	O	O	O	O
screening	screening	O	O	O	O
for	for	O	O	O	O
medications	medications	O	O	O	O
and	and	O	O	O	O
underlying	underlying	O	O	O	O
conditions	conditions	O	O	O	O
predisposing	predisposing	O	O	O	O
to	to	O	O	O	O
hypocalcemia	hypocalcemia	O	DISEASE	OTHERS	I
is	is	O	O	O	O
recommended	recommended	O	O	O	O
to	to	O	O	O	O
help	help	O	O	O	O
prevent	prevent	O	O	O	O
severe	severe	O	O	O	O
reactions	reactions	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
citrate	citrate	CHEMICALS	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Laboratory	laboratory	O	O	O	O
measurement	measurement	O	O	O	O
of	of	O	O	O	O
pre-procedure	pre-procedure	O	O	O	O
serum	serum	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
in	in	O	O	O	O
selected	selected	O	O	O	O
donors	donors	O	O	O	O
may	may	O	O	O	O
identify	identify	O	O	O	O
cases	cases	O	O	O	O
requiring	requiring	O	O	O	O
heightened	heightened	O	O	O	O
vigilance	vigilance	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
case	case	O	O	O	O
also	also	O	O	O	O
illustrates	illustrates	O	O	O	O
the	the	O	O	O	O
importance	importance	O	O	O	O
of	of	O	O	O	O
maintaining	maintaining	O	O	O	O
preparedness	preparedness	O	O	O	O
for	for	O	O	O	O
managing	managing	O	O	O	O
rare	rare	O	O	O	O
but	but	O	O	O	O
serious	serious	O	O	O	O
reactions	reactions	O	O	O	O
in	in	O	O	O	O
volunteer	volunteer	O	O	O	O
apheresis	apheresis	O	O	O	O
blood	blood	O	O	O	O
donors	donors	O	O	O	O
.	.	O	O	O	O

